{"result": "(\"entity\"<|>CHAPMAN LC<|>PERSON<|>Chapman LC is an author who contributed to research on renal clearance of calcium, magnesium, and inorganic phosphate in humans.)\n##\n(\"entity\"<|>VARRADY PD<|>PERSON<|>Varrady PD is an author who collaborated on the study of urea-saline diuresis and its effects on renal clearance.)\n##\n(\"entity\"<|>KLEEMAN CR<|>PERSON<|>Kleeman CR is an author involved in the research regarding renal clearance and urea-saline diuresis.)\n##\n(\"entity\"<|>DE SOLÁ-MORALES O<|>PERSON<|>De Solá-Morales O is an author who conducted a systematic review on the use of urea for managing inappropriate secretion of ADH.)\n##\n(\"entity\"<|>RIERA M<|>PERSON<|>Riera M is an author who co-authored the systematic review on urea for managing inappropriate secretion of ADH.)\n##\n(\"entity\"<|>DECAUX G<|>PERSON<|>Decaux G is an author who researched the treatment of inappropriate secretion of antidiuretic hormone with furosemide.)\n##\n(\"entity\"<|>WATERLOT Y<|>PERSON<|>Waterlot Y is an author who contributed to the study on inappropriate secretion of antidiuretic hormone.)\n##\n(\"entity\"<|>GENETTE F<|>PERSON<|>Genette F is an author involved in the research on inappropriate secretion of antidiuretic hormone.)\n##\n(\"entity\"<|>HALLEMANS R<|>PERSON<|>Hallemans R is an author who worked on the treatment of inappropriate secretion of antidiuretic hormone.)\n##\n(\"entity\"<|>DEMANET JC<|>PERSON<|>Demanet JC is an author who contributed to the research on inappropriate secretion of antidiuretic hormone.)\n##\n(\"entity\"<|>VERBALIS JG<|>PERSON<|>Verbalis JG is an author who assessed the efficacy and safety of conivaptan in patients with euvolemic hyponatremia.)\n##\n(\"entity\"<|>ZELTSER D<|>PERSON<|>Zeltser D is an author who collaborated on the study of conivaptan for hyponatremic neuro-ICU patients.)\n##\n(\"entity\"<|>SMITH N<|>PERSON<|>Smith N is an author involved in the assessment of conivaptan for hyponatremic neuro-ICU patients.)\n##\n(\"entity\"<|>BARVE A<|>PERSON<|>Barve A is an author who contributed to the study on the efficacy of conivaptan in patients with euvolemic hyponatremia.)\n##\n(\"entity\"<|>ANDOH M<|>PERSON<|>Andoh M is an author who participated in the research on conivaptan for hyponatremic patients.)\n##\n(\"entity\"<|>BERL T<|>PERSON<|>Berl T is an author who researched the safety and effectiveness of oral tolvaptan in chronic hyponatremia.)\n##\n(\"entity\"<|>QUITTNAT-PELLETIER F<|>PERSON<|>Quittnat-Pelletier F is an author involved in the study of oral tolvaptan for chronic hyponatremia.)\n##\n(\"entity\"<|>VERBALIS JG<|>PERSON<|>Verbalis JG is an author who contributed to the research on oral tolvaptan in chronic hyponatremia.)\n##\n(\"entity\"<|>SCHRIER RW<|>PERSON<|>Schrier RW is an author who worked on the study of oral tolvaptan for chronic hyponatremia.)\n##\n(\"entity\"<|>BICHET DG<|>PERSON<|>Bichet DG is an author involved in the research on oral tolvaptan for chronic hyponatremia.)\n##\n(\"entity\"<|>OUYANG J<|>PERSON<|>Ouyang J is an author who contributed to the study of oral tolvaptan in chronic hyponatremia.)\n##\n(\"entity\"<|>SALTWATER INVESTIGATORS<|>ORGANIZATION<|>The SALTWATER Investigators is a group that conducted research on the safety and effectiveness of oral tolvaptan in chronic hyponatremia.)\n##\n(\"entity\"<|>RUNKLE I<|>PERSON<|>Runkle I is an author who reported on the experience with tolvaptan in treating hyponatremia secondary to SIADH.)\n##\n(\"entity\"<|>GOMEZ HOYOS E<|>PERSON<|>Gomez Hoyos E is an author who contributed to the study on tolvaptan for treating hyponatremia.)\n##\n(\"entity\"<|>RECIO BLÁZQUEZ L<|>PERSON<|>Recio Blázquez L is an author involved in the research on tolvaptan for hyponatremia.)\n##\n(\"entity\"<|>CUESTA HERNÁNDEZ M<|>PERSON<|>Cuesta Hernández M is an author who worked on the study of tolvaptan for hyponatremia.)\n##\n(\"entity\"<|>DE MIGUEL NOVOA MP<|>PERSON<|>De Miguel Novoa MP is an author who contributed to the research on tolvaptan for hyponatremia.)\n##\n(\"entity\"<|>RUIZ GRACIA T<|>PERSON<|>Ruiz Gracia T is an author who reported on the progressive reduction of tolvaptan doses in chronic SIADH treatment.)\n##\n(\"entity\"<|>ORTOLÁ A<|>PERSON<|>Ortolá A is an author involved in the study of tolvaptan for chronic SIADH treatment.)\n##\n(\"entity\"<|>CRESPO I<|>PERSON<|>Crespo I is an author who contributed to the research on tolvaptan for chronic SIADH treatment.)\n##\n(\"entity\"<|>SANTIAGO A<|>PERSON<|>Santiago A is an author involved in the study of tolvaptan for chronic SIADH treatment.)\n##\n(\"entity\"<|>NUTRICIÓN PEDIÁTRICA<|>EVENT<|>NUTRICIÓN PEDIÁTRICA is a topic discussed in the context of pediatric nutrition and dietary recommendations.)\n##\n(\"relationship\"<|>CHAPMAN LC<|>VARRADY PD<|>Chapman LC and Varrady PD co-authored a study on renal clearance of minerals in humans<|>8)\n##\n(\"relationship\"<|>CHAPMAN LC<|>KLEEMAN CR<|>Chapman LC and Kleeman CR collaborated on research regarding renal clearance<|>8)\n##\n(\"relationship\"<|>VARRADY PD<|>KLEEMAN CR<|>Varrady PD and Kleeman CR co-authored a study on renal clearance<|>8)\n##\n(\"relationship\"<|>DE SOLÁ-MORALES O<|>RIERA M<|>De Solá-Morales O and Riera M co-authored a systematic review on urea for managing inappropriate secretion of ADH<|>8)\n##\n(\"relationship\"<|>DECAUX G<|>WATERLOT Y<|>Decaux G and Waterlot Y collaborated on research regarding inappropriate secretion of antidiuretic hormone<|>8)\n##\n(\"relationship\"<|>DECAUX G<|>GENETTE F<|>Decaux G and Genette F co-authored a study on inappropriate secretion of antidiuretic hormone<|>8)\n##\n(\"relationship\"<|>DECAUX G<|>HALLEMANS R<|>Decaux G and Hallemans R worked together on research regarding inappropriate secretion of antidiuretic hormone<|>8)\n##\n(\"relationship\"<|>DECAUX G<|>DEMANET JC<|>Decaux G and Demanet JC collaborated on research regarding inappropriate secretion of antidiuretic hormone<|>8)\n##\n(\"relationship\"<|>VERBALIS JG<|>ZELTSER D<|>Verbalis JG and Zeltser D co-authored a study on conivaptan for hyponatremic neuro-ICU patients<|>8)\n##\n(\"relationship\"<|>VERBALIS JG<|>SMITH N<|>Verbalis JG and Smith N collaborated on the assessment of conivaptan<|>8)\n##\n(\"relationship\"<|>VERBALIS JG<|>BARVE A<|>Verbalis JG and Barve A co-authored a study on the efficacy of conivaptan<|>8)\n##\n(\"relationship\"<|>VERBALIS JG<|>ANDOH M<|>Verbalis JG and Andoh M worked together on research regarding conivaptan<|>8)\n##\n(\"relationship\"<|>BERL T<|>QUITTNAT-PELLETIER F<|>Berl T and Quittnat-Pelletier F co-authored a study on oral tolvaptan for chronic hyponatremia<|>8)\n##\n(\"relationship\"<|>BERL T<|>VERBALIS JG<|>Berl T and Verbalis JG collaborated on research regarding oral tolvaptan<|>8)\n##\n(\"relationship\"<|>RUNKLE I<|>GOMEZ HOYOS E<|>Runkle I and Gomez Hoyos E co-authored a study on tolvaptan for treating hyponatremia<|>8)\n##\n(\"relationship\"<|>RUNKLE I<|>RECIO BLÁZQUEZ L<|>Runkle I and Recio Blázquez L collaborated on research regarding tolvaptan<|>8)\n##\n(\"relationship\"<|>RUNKLE I<|>CUESTA HERNÁNDEZ M<|>Runkle I and Cuesta Hernández M co-authored a study on tolvaptan<|>8)\n##\n(\"relationship\"<|>RUNKLE I<|>DE MIGUEL NOVOA MP<|>Runkle I and De Miguel Novoa MP collaborated on research regarding tolvaptan<|>8)\n##\n(\"relationship\"<|>RUIZ GRACIA T<|>ORTOLÁ A<|>Ruiz Gracia T and Ortolá A co-authored a study on tolvaptan for chronic SIADH treatment<|>8)\n##\n(\"relationship\"<|>RUIZ GRACIA T<|>CRESPO I<|>Ruiz Gracia T and Crespo I collaborated on research regarding tolvaptan<|>8)\n##\n(\"relationship\"<|>RUIZ GRACIA T<|>SANTIAGO A<|>Ruiz Gracia T and Santiago A co-authored a study on tolvaptan<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Chapman LC, Varrady PD, Kleeman CR. Effect of urea-saline diuresis on renal clearance of calcium, magnesium, and inorganic phosphate in man. Proc Soc Exp Biol Med. 1966; 121(2):592-6.\n\n75. De Solá-Morales O, Riera M. Urea for management of the syndrome of inappropriate secretion of ADH: a systematic review. Endocrinol Nutr. 2014; 61:486-92.\n\n76. Decaux G, Waterlot Y, Genette F, Hallemans R, Demanet JC. Inappropriate secretion of antidiuretic hormone treated with furosemide. Br Med J Clin Res Ed. 1982; 285(6335):89-90.\n\n77. Decaux G. Treatment of the syndome of inappropriate secretion of antidiuretic hormone by long loop diuretics. Nephron. 1983; 35:82-8.\n\n78. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intrave-\n---\nTema 51. Metabolismo hídrico en los pacientes con nutrición artificial...    817\n\nnous conivaptan in patients with euvolemic hypo-\nnatremi. subgroup analysis of a randomized, con-\ntroled study. Clin Endocrinol Oxf. 2008; 69:159-68.\n\n79. Naidech AM, Paparello J, Liebling SM, Bassin SL,\n    Levaseur K, Alberts MJ, et al. Use of conivaptan\n    (vaprisol) for hyponatremic neuro-ICU patients.\n    Neurocrit Care. 2010; 13:57-61.\n\n80. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW,\n    Bichet DG, Ouyang J, et al. SALTWATER Investigators.\n    Oral tolvaptan is safe and effective in cronic hypona-\n    tremia. J Am Soc Nephrol. 2010; 21(4):705-12.\n\n81. Runkle I, Gomez Hoyos E, Recio Blázquez L, Cuesta\n    Hernández M, De Miguel Novoa MP, Ruiz Gracia\n    T, et al. Experiencia con una dosis inicial de 7,5 mg\n    de tolvaptan en el tratamiento de la hiponatremia\n    secundaria al SIADH. Abstrac 56 Congr SEENVa-\n    lencia Mayo 2014.\n\n82. Ruiz Gracia T, Ortolá A, Crespo I, Santiago A,\n    Gómez Hoyos E, Recio L, et al. Progressive reduc-\n    tion of tolvaptan doses in treatment of chronic\n    SIADH. 17th Eur Congr Endocrinol Endocr Abs-\n    trac. 2015.\n---\nThe image appears to be a blank white page. There is no visible content, text, diagrams, or any other information present in this image. Therefore, I cannot provide any markdown translation or description of content, as there is nothing to transcribe or describe.\n---\n# BLOQUE: NUTRICIÓN PEDIÁTRICA\n\n(Dr. José Manuel Moreno Villares)\n\n## TEMA 52. Valoración nutricional y patrones de referencia en el paciente en edad pediátrica.\nDras. Cecilia Martínez Costa y Elena Crehuá Gaudiza\n\n## TEMA 53. Recomendaciones dietéticas en el paciente en edad pediátrica.\nDras. Susana Redecillas Ferreiro, Raquel Núñez Ramos y Raquel Lorite Cuenca\n\n## TEMA 54. Nutrición enteral en el paciente en edad pediátrica: vías y fórmulas.\nDres. Ana Belén Martínez Zazo, Óscar Rubio Cabezas y Consuelo Pedrón Giner\n\n## TEMA 55. Nutrición parenteral en el paciente pediátrico: vías y fórmulas.\nDres. Marta Germán Díaz y José Manuel Moreno Villares\n---\nThe image appears to be a blank white page. There is no visible content, text, diagrams, or any other information present in this image. Therefore, I cannot provide any markdown translation or description of content, as there is nothing to transcribe or describe.\n---\n# Tema 52.\n## Valoración nutricional y patrones de referencia en el paciente en edad pediátrica\n\nCecilia Martínez Costa\nProfesora Titular de Pediatría. Sección de Gastroenterología y Nutrición Pediátrica. Hospital Clínico\nUniversitario. Valencia\n\nElena Crehuá Gaudiza\nSección de Gastroenterología y Nutrición Pediátrica. Servicio de Pediatría. Hospital Clínico\nUniversitario. Valencia\n\nDietoterapia, nutrición clínica y metabolismo. Tercera edición. Copyright 2017 de los autores, SEEN y Grupo Aula Médica.\nTodos los derechos reservados. Páginas 821-828.\n\n1. Introducción\n2. Anamnesis\n3. Exploración clínica\n4. Exploración antropométrica\n5. Expl\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}